Oral Anti Diabetes Drugs Market

SKU: DMPH2726 | Last Updated On: Nov 09 2022 | Available Formats

> Oral Anti Diabetes Drugs Market Expected to reach a high CAGR of 10.3% during the forecast period 2022-2029

Oral Anti Diabetes Drugs Market is segmented By Drug Class (DPP-4 Inhibitors, Sulfonylureas (Gliclazide, Glyburide, Glimepiride, Others), Meglitinides (Biguanides, Metformin, Repaglinide, Nateglinide, Others), Biguanides (Alpha-glycosidase inhibitors, Voglibose, Acarbose, Others), Other), By Dosage Type (Liquid, Capsule, Tablet), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029


Market Overview

[195 Pages Report] Oral Anti Diabetes Drugs Market size is expected to reach USD million by 2029, with growth at a high CAGR of 10.3% during the forecasting period (2022-2029). 

Diabetes is a chronic disease that occurs when the body cannot effectively use the produced insulin or the pancreas does not produce sufficient insulin. Diabetes is of two types: type 1 and type 2. About 90% of people with diabetes have type 2 diabetes. Over the recent years, the oral anti-diabetes drug has been witnessing considerable growth on the back of rising incidences of diabetes. As per DataM Intelligence, the research report provides detailed insights on the oral anti-diabetes drugs market size, trends, share, growth, demand, and competitive analysis in the major regions such as North America (United States, Canada), European Countries (Germany, Italy, UK, Spain, France, Russia), Latin America (Mexico, Argentina), Asia Pacific (China, India, Japan, South Korea), Middle East and Africa (Saudi Arabia, UAE, Qatar, and South Africa).

Oral Anti Diabetes Drugs Market Scope



Market CAGR


Segments Covered

By Drug Class, By Dosage Type, By Distribution Channel, and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America

For More Insights, Download Sample Brochure

Market Growth Dynamics

The global oral anti-diabetes drugs market growth is driven by the growing geriatric population, rising government initiatives, and continuous research and development conducted by pharmaceutical manufacturers. The significant growth in the market can be attributed to factors such as the rising prevalence of diabetes and the increasing number of programs initiated by various health organizations related to health awareness. In 2019, it was estimated that out of 511 million people suffering from diabetes, 31.3% were undiagnosed. In 2019, diabetes was the cause of 4.2 million deaths per year, making it the eighth leading cause of death, worldwide. The diabetic condition, on the whole, doubles the risk of death. Currently, about 10% of all diabetes cases are Type-1 and the remaining are Type-2. Thus, the rise in the prevalence of type-2 diabetes worldwide is likely to create a vast demand for diabetes drugs.

The rising prevalence of diabetes worldwide is likely to create a vast demand

Sedentary lifestyles & rise in cases of diabetes to leverage global oral anti-diabetes drugs market revenue

An inactive lifestyle, obesity, and higher stress are anticipated to boost the demand for oral anti-diabetic drugs over the forecast period. Apart from this, technological breakthroughs and medical compensation facilities are likely to impel the growth of the oral anti-diabetic drug market in the years ahead. Nevertheless, the increase in R&D activities and tremendous potential for the oral anti-diabetic drug market to grow will chart a profitable roadmap for the business over the forecast period, thereby normalizing the negative impact of hindrances on the oral anti-diabetic drug market.

The high cost of oral anti-diabetes drugs and the presence of alternate solutions is hindering the market growth

However, the rise in drug costs is projected to restrict the expansion of the oral anti-diabetic drug market in the forecast period. Also, the preferred use of insulin over oral anti-diabetes drugs and the complications associated with the drugs has been hindering the market growth.

COVID-19 Impact Analysis

Covid-19 pushes up sales of oral anti-diabetes drugs. Patients given these drugs had a mortality rate of 18 percent as compared with 37 percent in matched patients receiving only insulin according to the study involving seven Italian hospitals during the first surge of COVID cases last spring. The pandemic seems to impact the operation of pharmaceutical companies with those dealing in oral anti-diabetes drugs. Diabetics severely turned people into buying more medicines for these ailments. In June, demand for the Anti-Diabetic segment grew at 12.7 percent YoY due to continued buying during the period of the lockdown. Thus, the pandemic has increased the sale and ultimately the growth of the oral anti-diabetes drugs market in the forecast period.

Segment Analysis

DPP-4 Inhibitors  segment is expected to grow at the fastest CAGR during the forecast period (2021-2029)  

The Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors segment has the largest market share in the forecast period. DPP-4 inhibitor drugs are gaining momentum in the market because the products do not seem to have any effect on primary adverse cardiovascular outcomes and risk for heart failure. Besides, they can be used both as a combination therapy with insulin, sulphonylureas, and dipeptidyl peptidase-4 drugs and as a monotherapy, thus, making it a widely used class of drugs. During the forecast period, the DPP-4 inhibitors segment is expected to witness a constant growth rate, due to the introduction of new drugs that have improved efficacy, like glucagon-like peptide (GLP-1) and sodium-glucose co-transporter-2 (SGLT-2) inhibitors. The segment is still expected to maintain the largest market share among all oral anti-diabetes drugs market segments.

The sulfonylureas segment has the second-largest market share in the forecast period. These are sometimes called “oral hypoglycemic agents,” which work very differently than metformin. They signal the pancreas to release insulin and they also help the body’s cells use insulin better. Sulfonylureas may be old, but they’re effective. They can lower A1C levels (a measure of blood sugar control over the previous 2–3 months) by 1% to 2%. The affordability and higher glucose-lowering efficacy are possible advantages that explain why this drug class is frequently used in practice. However, concerns have been raised about why sulfonylureas should not be used as first-line therapy and should be avoided in use with metformin, due to concerns regarding severe cardiovascular and hypoglycemic risk.

Sulfonylureas are classified into two generations, first-generation and second-generation. Currently used are the second-generation sulfonylureas (Glyburide, Glipizide, Glimepiride, Glicazide), while the first-generation sulfonylureas are no longer used (Tolbutamide, Chlorpropamide, Tolazamide) due to severe hypoglycemia episodes. This drug class is typically used for patients with type 2 diabetes where cost is a major issue, patients who are not overweight, and for whom metformin is contraindicated, not well tolerated, or has failed to meet glycemic target goals. The most common adverse effects of sulfonylureas are hypoglycemia, weight gain, and risk for cardiovascular events. Clinicians initially prescribe lower doses of sulfonylureas to prevent the risks of hypoglycemia. Unfortunately, in some patients taking sulfonylureas, the adverse effects may outweigh the benefits.

Gliclazide: Gliclazide is used in the treatment of type 2 diabetes mellitus. It is used along with diet and exercise to improve blood sugar control in adults with type 2 diabetes. It is an anti-diabetic medication. It works by increasing the amount of insulin released by the pancreas to lower blood sugar levels. Gliclazide may also be called by the brand names Bilxona, Dacadis, Diamicron, Laaglyda, Nazdol, Vamju, Vitile, Ziclaseg, and Zicron.

Glipizide: Glipizide is an oral diabetes medicine that helps control blood sugar levels by helping your pancreas produce insulin. Glipizide is used together with diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus. Glipizide oral tablet is available as the brand-name drugs Glucotrol and Glucotrol XL. It’s also available as a generic drug. Generic drugs usually cost less. In some cases, they may not be available in every strength or form as the brand.

Glyburide:  Glyburide oral tablet comes as brand-name drugs and as generic drug. Brand names: Diabeta, Glynase PresTabs. Glyburide oral tablets come in two forms: regular and micronized. The micronized tablets contain smaller particles of the drug. Glyburide is used along with diet and exercise, and sometimes with other medications, to treat type 2 diabetes. Glyburide is in a class of medications called sulfonylureas. Glyburide lowers blood sugar by causing the pancreas to produce insulin.

Geographical Analysis

The North American region holds the largest market share global oral anti-diabetes drugs market

North American region is dominating the global oral anti-diabetes drugs market and accounted for the largest market share in 2020, owing to the large investment in healthcare and pressing schedules and unhealthy eating habits of people, primarily in the U.S. is said to be driving the market in the region. In addition, the growing sedentary lifestyle, presence of diabetes medicines on the Essential Drug List of the nations and wide insurance coverage for diabetes drugs have contributed to the growth rate of Oral anti-diabetes drugs in the region. Moreover, an increase in the launch of new drugs with improved efficacy and high reimbursement for medicines is expected to have a positive impact on the oral anti-diabetes drug market. The increasing incidence and prevalence of diabetes and the increasing healthcare expenditure in t countries are an indication of the increasing usage of oral anti-diabetes drugs.

Competitive Landscape

The oral anti-diabetes drugs market is moderately competitive with the presence of local as well as global companies.  Some of the key players which are contributing to the growth of the market include Glenmark Pharma, Abbott, Biocon, Sanofi, Sun pharma, Novartis, Novo Nordisk, Merck, GlaxoSmithKline, Piramal Healthcare, Bristol-Myers Squibb, Bayer Healthcare, Dr. Reddy’s Laboratories Ltd, and Pfizer among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the oral anti-diabetes drugs market globally.

Company Profile Analysis:

Glenmark Pharma

Overview: Glenmark Pharmaceuticals Limited is a global pharmaceutical company. The Company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, the United States, Latin America, Europe, and the Rest of the World (ROW). It has approximately seven molecules, over two NCEs, and approximately five NBEs in various stages of pre-clinical and clinical development. It is focused on developing and marketing branded and generic formulations. It focuses on manufacturing products across therapeutic areas of dermatology, respiratory, and oncology. Its active pharmaceuticals ingredients (API) business spans over 80 countries, including regulated markets of the United States, Europe, Japan, and Canada. Its products are primarily marketed in the United States and Western Europe. It has offices in over 40 countries and operates approximately 20 manufacturing facilities in over five countries. It operates over five research and development (R&D) centers.

Product Portfolio: The Company’s portfolio comprised 164 products including API business, an independent subsidiary called Glenmark Life Sciences, Glenmark Pharmaceuticals is focused on the areas of respiratory and dermatology.

Key Development:  In April 2019, Glenmark Pharma launch its anti-diabetes drug Remogliflozin in India. "Glenmark is the first company in the world to launch the novel SGLT2 inhibitor Remogliflozin and India is the first country to get access to this innovative drug. The drug is indicated in the treatment of type-2 diabetes mellitus in adults.

Trending Topics

Diabetes devises Market

Diabetes Therapeutics Market

Pericarditis Drugs Market


What is the Growth Rate of the Oral Anti-Diabetes Drugs Market?

Forecasted at 10.3% through the forecast period( 2022-2029).

What Companies Are Included in the Oral Anti-Diabetes Drugs Market?

The oral anti-significant diabetes drugs are competitive with the approach to life of worldwide and native companies. Among others, Glenmark Pharma, Abbott, Biocon, Sanofi, Pfizer, Novartis, and Novo Nordisk are among the key players leading to the growth of the marketplace.

What is The COVID-19 Impact on Oral Anti-Diabetes Drugs Market?

Sales of oral anti-support diabetes drugs increase after Covid 19. The death count for patients having these drugs was below percent when compared with 37 percent for combined patients who received simply insulin. The pandemic looks to impact the techniques of pharmaceutical companies dealing with oral anti supports diabetes drugs.

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report

20% Discount Applied*

Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!